ACSL5 Mouse Monoclonal Antibody [Clone ID: OTI3A3]

CAT#: TA811897

ACSL5 mouse monoclonal antibody,clone OTI3A3

Size: 30 ul 100 ul

Formulation: Standard Carrier Free

Conjugation: Unconjugated Biotin HRP



  View other "OTI3A3" antibodies (4)

Need it in bulk or conjugated?
Get a free quote

【特别福利】购一抗正装产品,免费领10ul抗体试用装

CNY 1,999.00

CNY 2,700.00


货期*
现货

规格
    • 100 ul

Product images

经常一起买 (4)
Transient overexpression lysate of acyl-CoA synthetase long-chain family member 5 (ACSL5), transcript variant 2
    • 100 ug

CNY 4,840.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human acyl-CoA synthetase long-chain family member 5 (ACSL5), transcript variant 2, 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Recombinant protein of human acyl-CoA synthetase long-chain family member 5 (ACSL5), transcript variant 2, 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Clone Name OTI3A3
Applications IHC, WB
Recommend Dilution WB 1:500, IHC 1:500
Reactivity Human
Host Mouse
Clonality Monoclonal
Immunogen Human recombinant protein fragment corresponding to amino acids 104-620 of human ACSL5 (NP_976313) produced in E.coli.
Formulation PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
Concentration 1 mg/ml
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 75.8 kDa
Gene Name acyl-CoA synthetase long-chain family member 5
Synonyms ACS2; ACS5; FACL5
Reference Data
Protein Families Transmembrane
Protein Pathways Adipocytokine signaling pathway, Fatty acid metabolism, Metabolic pathways, PPAR signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...